Page 304 - 2021_02-Haematologica-web

618
Letters to the Editor
with leukemia phenotype. Acta Haematol. 2013;129(2):78-82.
11. Perna F, Abdel-Wahab O, Levine RL, Jhanwar SC, Imada K, Nimer SD. ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. Haematologica.
2011;96(2):342-343.
12. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau
MM, et al. The 2016 revision to the World Health Organization clas- sification of myeloid neoplasms and acute leukemia. Blood. 2016; May 19;127(20):2391-405.
13. Sakai H, Hosono N, Nakazawa H, et al. A novel genetic and mor- phologic phenotype of ARID2-mediated myelodysplasia. Leukemia. 2018;32(3):839-843.
14. Haferlach C, Bacher U, Kohlmann A, et al. CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the mini-
mally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia. Haematologica. 2011;96(6):829-836.
15. Haferlach C, Bacher U, Schnittger S, et al. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer. 2012; 51(4):328-337.
16. Choi SI, Jang MA, Jeong WJ, et al. A case of chronic myeloid leukemia with rare variant ETV6/ABL1 rearrangement. Ann Lab Med. 2017;37(1):77-80.
17. Million RP, Harakawa N, Roumiantsev S, Varticovski L, Van Etten RA. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol. 2004;24(11):4685-4695.
haematologica | 2021; 106(2)